Here we further elucidate that genetic silencing of SRA using shRNA increased the immunogenicity of DCs that have captured the hsp110-gp100 vaccine, assessed by DC-mediated activation of gp10025-33-specific T cells in vitro and in vivo, acquisition of cytolytic activity by T cells, growth inhibition of established melanoma, and prolonged mouse survival following DC immunization. The gene discussed is HSPH1; the disease is melanoma.